抗血小板药物联合应用对人体的影响：阿司匹林、曲匹地尔、噻氯匹定和双嘧达莫的联合应用

Effect of the combination of antiplatelet agents in man: combination of aspirin, trapidil, ticlopidine and dipyridamole.

作者信息

Nagakawa Y, Akedo Y, Orimo H, Yano H

机构信息

Department of Geriatrics, Faculty of Medicine, University of Tokyo, Japan.

出版信息

Thromb Res. 1990 Dec 15;60(6):469-75. doi: 10.1016/0049-3848(90)90231-z.

DOI:10.1016/0049-3848(90)90231-z

PMID:2082479

Abstract

An in vitro study of how platelet aggregation would be inhibited by the combination of aspirin or ticlopidine irreversibly inhibitory to platelet aggregation and trapidil or dipyridamole reversibly inhibitory, was carried out. The measured 50% inhibition concentrations indicated that aspirin was most inhibitory to collagen-induced platelet aggregation, followed by trapidil, ticlopidine and dipyridamole in decreasing sequence of inhibition. The combination of either aspirin or ticlopidine with trapidil inhibited platelet aggregation more intensely than the combination of either agent with dipyridamole. Thus, in clinical use of aspirin or ticlopidine, it may be expected that the lower dosage of aspirin or ticlopidine with lower frequencies of side effects inhibits platelet aggregation effectively with the combination of trapidil rather than dipyridamole.

摘要

进行了一项体外研究，以探讨阿司匹林或噻氯匹定（对血小板聚集有不可逆抑制作用）与曲匹地尔或双嘧达莫（对血小板聚集有可逆抑制作用）联合使用时如何抑制血小板聚集。测得的50%抑制浓度表明，阿司匹林对胶原诱导的血小板聚集抑制作用最强，其次是曲匹地尔、噻氯匹定和双嘧达莫，抑制作用依次递减。阿司匹林或噻氯匹定与曲匹地尔联合使用比与双嘧达莫联合使用更强烈地抑制血小板聚集。因此，在阿司匹林或噻氯匹定的临床应用中，可以预期较低剂量的阿司匹林或噻氯匹定（副作用频率较低）与曲匹地尔联合使用而非与双嘧达莫联合使用时能有效抑制血小板聚集。